ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1385

Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome

Giovanni Fulvio1, Rossana Izzetti2, Francesco Gulia2, Valentina Donati3, Gaetano La Rocca4, Inmaculada Concepción Navarro García5, Beatrice Dei1, Francesco Ferro6, Marta Mosca7 and Chiara Baldini7, 1Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 2University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Unit of Dentistry and Oral Surgery, Pisa, Italy, 3Azienda Ospedaliero-Universitaria Pisana (AOUP), Unit of Pathological Anatomy 2, Pisa, Italy, 4University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, 5University of Pisa, Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, 6Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 7University of Pisa, Pisa, Pisa, Italy

Meeting: ACR Convergence 2025

Keywords: hand, Outcome measures, Sjögren's syndrome, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Ocular and oral dryness, occurring in isolation, represent distinct phenotypic subsets within Sjögren’s disease (SjD). However, potential differences in glandular imaging findings and pathophysiological mechanisms have not yet been adequately investigated. This study investigates how isolated ocular, isolated oral, and combined dryness phenotypes in SjD differ with respect to ultrasonographic patterns, histological findings, functional test outcomes, and patient-reported metrics

Methods: We retrospectively reviewed patients diagnosed with SjD based on the 2016 EULAR/ACR criteria from January 2017 to December 2024. All participants underwent labial gland biopsies and comprehensive imaging using high-frequency ultrasonography: 18 MHz for major salivary glands (SGUS), 48 MHz for lacrimal glands (LGUHFUS), and 70 MHz for labial salivary glands (LSGUHFUS). A semiquantitative OMERACT score (0–3) was used to define abnormal imaging (score ≥2). Patient-reported outcome (PRO) included the ESSPRI, OSDI, OHIP, and VAS scores for oral and ocular dryness. Dryness was categorized into four groups based on VAS scores: no dryness (VAS ocular< 5, VAS oral < 5), isolated ocular dryness (VAS ocular ≥5, VAS oral < 5), isolated oral dryness, (VAS ocular< 5, VAS oral ≥5) and double dryness (VAS ocular≥5, VAS oral≥5). In addition, patients presenting with either ocular dryness or oral dryness were analyzed separately. Systemic disease activity was evaluated using the ESSDAI score while functional assessment included unstimulated salivary flow rate (USWR) and the Schirmer’s test

Results: Among 191 SjD patients (mean age 55.3 ± 1.9 years; 8.4% male), 22 had no dryness, 32 isolated ocular, 24 isolated oral, and 113 both symptoms. PROs scores followed a gradient, with the double dryness group reporting the highest symptom burden, the no dryness group the lowest, and the isolated dryness groups falling in between (see Fig.1). Quality of Life (QoL) scores were higher in the no dryness group. Patients with isolated ocular dryness exhibited lower Schirmer’s test values compared to those with no dryness and isolated oral dryness (5.6±2.0 vs 12.2±3.5 and 6.2±2.4 respectively), but higher than double dryness (5.0±0.8, p< 0.001). Similarly, patients with isolated oral dryness had lower USWR than those with no dryness or isolated ocular dryness (2.9±1.5 vs 3.5±1.7 and 3.7±1.1 respectively), but higher than patients with double dryness (1.8±0.4) (Tab.1). No significant differences were observed in labial salivary gland histology or in the ultrasonographic findings of the lacrimal, labial, and major salivary glands. Finally, ESSDAI scores were lower in isolated ocular (2.8±1.1) and oral dryness (3.9±1.4) compared to no dryness (4.7±1.2) or double dryness (5.6±1.1)

Conclusion: In SjD isolated ocular and oral dryness are linked to specific functional deficits in the lacrimal and salivary glands, respectively. However, these isolated forms do not exhibit significant differences in histological features or glandular ultrasonographic findings. Clinically, isolated dryness appears to define a milder and distinct phenotype of SjD, marked by limited systemic involvement and a moderate burden on patient-reported outcomes

Supporting image 1Figure 1 – Comparative Analysis of Patient-Reported Outcomes Across Dryness Phenotypes in Sjögren’s Syndrome

This radar chart illustrates the differences in various patient-reported outcomes including quality of life (QoL), Oral Health Impact Profile (OHIP), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), and Visual Analogue Scale (VAS) assessments for ocular and oral dryness, total dryness, pain, and fatigue. Each colour represents a different group: no dryness (blue), isolated ocular dryness (red), isolated oral dryness (orange), and double dryness (green), highlighting their respective impacts on the dimensions assessed.

Supporting image 2Table 1 – Demographic and Clinical Characteristics of Sjögren’s Syndrome Patients by Dryness Phenotype

This table presents a comprehensive comparison of demographic and clinical parameters among Sjögren’s syndrome patients categorized into no dryness, isolated ocular dryness, isolated oral dryness, double dryness, and combined isolated ocular or oral dryness groups. Key parameters include age, gender distribution, Ocular Surface Disease Index (OSDI), unstimulated salivary flow rate (USWR), Schirmer’s test scores, Focus Score, Ectopic Lymphoid Structures (ELS), Major Salivary Gland Ultrasonography (SGUS), Lacrimal Gland Ultrasonography (LGUHFUS), labial salivary glands (LSGUHFUS) and EULAR Sjögren’s syndrome disease activity index (ESSDAI).


Disclosures: G. Fulvio: None; R. Izzetti: None; F. Gulia: None; V. Donati: None; G. La Rocca: None; I. Navarro García: None; B. Dei: None; F. Ferro: None; M. Mosca: AbbVie, 2, AstraZeneca, 2, 6, Biogen, 2, BMS, 2, Eli Lilly, 6, GSK, 2, 5, 6, Idorsia, 2, Milteny, 2, Novartis, 2, Otsuka, 2, 6, UCB, 2, 6; C. Baldini: None.

To cite this abstract in AMA style:

Fulvio G, Izzetti R, Gulia F, Donati V, La Rocca G, Navarro García I, Dei B, Ferro F, Mosca M, Baldini C. Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/characterizing-isolated-dryness-phenotypes-in-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-isolated-dryness-phenotypes-in-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology